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Abstract We defined the role of urokinase plasminogen 
activator (uPA) and its growth factor-like domain (GFD) in 
stimulating smooth muscle cell (SMC) migration. Recombinant 
uPA (r-uPA) stimulated migration approximately 3-fold whilst 
the recombinant uPA mutant containing an altered GFD (r- 
uPAmut) was ineffective. Both uPA variants bound to the same 
high affinity receptor in a competitive manner. FGF-2- and 
PDGF-BB-induced migration was also dependent on uPA, their 
effects being antagonized by addition of a uPA-neutralizing 
antibody or the r-uPAmut. Thus r-uPA is chemotactic for SMC 
and stimulation of cell migration by PDGF-BB and FGF-2 is 
dependent on uPA. The GFD of uPA is essential for its 
chemotactic effects. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Migration of vascular smooth muscle cells (SMC) is funda- 
mental to the development of diffuse intimal thickenings, 
atherosclerotic lesions [1], and vessel wall remodelling [2,3]. 
SMC migration is regulated by vascular-derived growth fac- 
tors [4-7], which also appear to control the ability of migrat- 
ing cells to produce various proteolytic enzymes [7 9]. In- 
crease of proteolytic activity within the vessel wall promotes 
atherosclerotic plaque instability and thrombolysis at the lu- 
minal surface of atherosclerotic lesions [10]. Plasminogen ac- 
tivators (PAl. which release plasmin, possessing the broad 
substrate specificity, have crucial roles in such processes 
[4,11]. Urokinase PA (uPA), interacting with its receptor 
(uPAR), either alone or complexed with PA inhibitor (PAIl, 
induces highly regulated proteolysis associated with cell mi- 
gration [12] and also has the potential to participate in cell 
signalling processes required for migration [13 15]. In this 
study we demonstrate that uPA is highly chemotactic for 
SMC and the ability of FGF-2 to induce migration can be 
attributed to the chemotactic activity of uPA; PDGF-induced 
cell migration also exhibits a dependency on uPA. Chemo- 
tactic acti, ity of uPA is highly dependent on the growth fac- 
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tor-like domain (GFD) and antagonism of uPA at its receptor 
by a recombinant uPA containing a mutated growth factor- 
like domain (r-uPAmut) prevents this ability of uPA to induce 
SMC to migrate. 
2. Materials and methods 
2.1. MateriaA' 
Chemicals and products for cell culture were purchased either from 
Sigma (St. Louis, MO), Pharmacia LKB Biotechnology (Uppsala, 
Sweden), Merk (Darmstadt, Germany) or Serva (Heidelberg, Ger- 
many). Nate~l was obtained t¥om Amershanr International (Little 
Chall\mt. GB). PDGF-BB and FGF-2 were purchased from Sigma. 
2.2. Recombinant pro-uPA-mutanl amt pro-uP.,t 
Preparation of the r-uPA containing an altered growth t,tctor-like 
domain (r-uPAmut) involved transformation of K colt (K-12JMlll9 
strain) with a pUABC plasmid (4.11 kbp) containing an Xhal-Bgll- 
fragment (1.39 kbp) with an origin of replication, promotor and op- 
erator sequences of the lac-operon from the pUCI9 vector; the Bgll- 
P,ulq'ragment 11.28 kbp), containing [3-1actamase from the pUCI8 
vector and BglI-Xhal-cDNA fragment ( 1.44 kbp) of human urokmasc 
gene. The r-uPAmut is distinct from the wild type of pro-uPA (r-uPA} 
with the first N-terminal 24 amino acids, SNELHQVPSNCDC- 
LNGGTCVSNKY, replaced by [TPSLHACRSTLD [16]. The pUABC 
plasmid encoding r-uPAmut consisted of pUCIg and pUCI9 vectors 
and human urokinase cDNA fiagments Scal-EcoR[ (0.42 kbp), 
EcoRl-EcoR1 t0.42 kbp) and EcoRI-Pstl (0.6 kbp), obtained by im- 
muno- and oligonucleotide screening of eDNA HL 101 lb library on 
the base of gtll (CLONTECH Laboratories, Inc.). Its construction 
included digestion of pUCI8 with EcoR1 and Pstl, followed by liga- 
tion of the fragments with the EcoRI-Pstl-fragment (0.6 kbp) of the 
urokinase cDNA using bacteriophage T4 DNAdigase. Subsequently 
theplasmidp[ICI8 uro1039 1642 was isolated from the E. colitrans- 
[\~rmed cells. The pUCI9_uro204 623 plasmid was prepared by diges- 
tion of pUCI9 with Xhal, t\~llowed by Klenow fragment DNA po- 
lymerase reaction, cutting with EcoRl and ligation with the Scal- 
EcoRl-fragment (0.42 kbp) of the uPA cDNA. Construction of the 
pl!Cl9_uro204 623/1039 1642 plasmid was achieved through cleav- 
age of pUClS_uro1039 1642 and pt!C19 uro2(14 623 with EcoRl 
and Bgll, followed by ligation of the resultan! 0.77 kbp and 1.1 kbp 
fragments of the pUCI8 uro1(139 1642 plasmid with the I.g kbp frag- 
metat of the pUCI9 uro204 623 plasmid. The resultant pU- 
C19 uro204-623/1039 1642 plasmid was then digested with EcoRl, 
dephosphorylated and ligated with the uPA (EcoRI-EcoRl: {).42 
kbp) cDNA fragment. Its structure was conlirmed by BamHl and 
Bamll digestion. The plasmid containing wild type of pro-uPA (r- 
uPA) eDNA was similarly constructed using the urokinase l'aql- 
EcoRl (0.47 kbp) cDNA fragment and ligation with the following 
two oligonucleotides: AATTCGAACGAACTGCAT('AGGTTCC- 
GT and CGACGGAACCTGATGCAGTTCGTTCG. Recombinant 
uPA and r-uPAmut primary structures were contirmed by DNA se- 
quencing and N-terminal amino acid sequencing of peptides, purified 
by methods including denaturation with urea, reconstitution and af- 
tinity chromatography. Their purity was greater than 90% and follov,- 
ing activation by' plasmin, their activities ranged between l 1.2x 10-' 
U/rag protein. 
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2.3. Preparation of anti-uPA antibodies 
The anti-uPA polyclonal antibodies were prepared by immunization 
of the rabbits with human urinary urokinase, purified as described 
previously [17]. The anti-uPA IgG exhibited a high affinity for uPA 
and recognized all forms of uPA, including urinary human uPA, 
human recombinant uPA variants, rat and bovine uPA, but not tissue 
plasminogen activator or plasminogen. 
2.4. Cell culture 
Rat aortic medial SMC isolated as described previously [18], were 
cultured at 37°C in a 5% CO2 incubator in Dulbecco's modified Ea- 
gle's medium (DMEM/FCS), containing 4 mM glutamine, 20 mM 
HEPES (pH 7.3), 100 U/ml penicillin, 100 U/ml streptomycin and 
10% FCS. Immunohistochemical staining confirmed that all first pas- 
sage SMC expressed smooth muscle ct-actin but not Factor VIII. 
SMC were used between passage 8 and 15. 
2.5. Chemotaxis assay 
Chemotactic assays were performed as previously described [19] 
using a micro-Boyden chamber apparatus (Neuroprobe Inc., Cabin 
John, MD). Briefly, confluent SMC, serum-deprived for 24 h in 
DMEM containing 0.1% BSA (DMEM/0.1%BSA), were briefly sub- 
jected to trypsin/EDTA, washed and resuspended in DMEM/ 
0.1%BSA. Between 3× 104 and 5× 104 SMC were then placed into 
the 50 btl upper wells of the Boyden chamber fitted with a PVP-free 
8 pm pore membrane (Nuclepore Corp., Palo Alto, CA), coated with 
collagen type I (100 l.tg/ml) (Vitrogen 100, Celtrix Pharmaceuticals 
Inc., Santa Clara, CA). Growth factors or the different forms of 
uPA in DMEM/0.1% BSA were added to in the lower chambers. In 
some instances (see Section 3: Results) the suspended SMC were 
preincubated with either the polyclonal uPA antibody (120 ~g/ml), 
r-uPA or r-uPAmut for 1 h at 37°C prior to their placement into 
the upper wells of the Boyden Chamber. Cells in the Boyden chamber 
were incubated for 4 h at 37°C in the CO2-incubator. The SMC which 
migrated through the pores of the membrane then were fixed in meth- 
anol, and stained with Dif Quick stain (Baxter) (the non-migrated 
cells were scraped off before staining). The membranes were then 
scanned using the 'Deskscan' and 'NIH Image' programs. Intensities 
from such scans represent the number of migrated SMC and are 
reported as peak area of the scanned field of stained SMC, expressed 
as percentage of control, i.e. migrated SMC not exposed to growth 
factors or the uPA variants. 
2.6. ie51-r-uPA binding to SMC 
Recombinant uPA and r-uPAmut were iodinated using Na1251 and 
Iodogen at room temperature [20]. The SMC were incubated at 4°C 
with shaking for 3 h with 125I-r-uPA or 125I-r-uPAmut either without 
or with 100-fold excess of cold r-uPA or r-uPAmut for determination 
of the non-specific binding. In the competitive binding studies varying 
concentrations of 'cold' uPA or uPAmut (see Section 3: Results) were 
added together with either 3 nM 125I-r-uPA or 125I-r-uPAmut. With 
the incubation completed, cells were washed with ice-cold PBS/ 
0.1%BSA (× 5) and lysed. Radioactivity in the cell lysates was meas- 
ured using a gamma counter. 
Table 1 
Increases in SMC migration, 
and presence of the r-uPAmut 
stimulated by r-uPA in the absence 
Recombinant uPA 
(nM) 
SMC migration (fold stimulation) 
Recombinant uPAmut 
0 nM 100 nM 
0 1.00 0.82 + 0.05* 
20 1.81 + 0.06 1.29 + 0.07" 
200 1.92+0.11 1.54+0.1" 
500 2.07 _+ 0.15 1.93 + 0.17 
SMC migration was determined in the micro Boyden chamber as 
described in the Methods in Section 2 and represents the means 
+ S.E.M. of 4 to 5 experiments. Fold stimulation represents increases 
in the number of migrating SMC above that observed in DMEM/ 
0.1%. *p < 0.05 from SMC migration in the absence of r-uPAmut. 
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Fig. 1. Concentration-dependent effects of r-uPA (O) and r-uPAmut 
(O) on SMC migration. SMC were exposed to concentration gra- 
dients of r-uPA and r-uPAmut in a micro Boyden chamber and 
SMC migrated through the 8 /am pores of the membrane measured 
4 h later. Results are expressed as fold stimulation relative to SMC 
migration in the absence of the uPA variants and are mean + S.E.M. 
of 4 or 5 experiments. 
3. Results 
3.1. Recombinant uPA, uPAR and SMC migration 
Recombinant  uPA elicited a dose-dependent chemotactic 
response in SMC with maximal (,-~ 3-fold) increases at ap- 
proximately 10 nM (p < 0.01); half  maximal effects occurred 
at approximately 5 nM (Fig. 1). Addit ion of excess anti -uPA 
ant ibody inhibited the r-uPA-induced, but not the basal level 
of SMC migration (data not shown). 
125I-r-uPA bound to the SMC with high affinity, similar to 
its ECs0 for inducing SMC migration. Scatchard analysis of 
the binding isotherms indicated an affinity of binding (Kd) 
averaging 7.2_+2.1 nM. Binding sites appeared to be of a 
single type, averaging 3× 10 `5 sites/cell (Fig. 2). Recombinant  
12~I-uPAmut also bound to the uPAR on SMC 
(Kd '~16.3 _+1.6 nM;  Bm~'~3×105 sites/cell) (data not 
shown). In addition, r -uPAmut competed with a2~SI-r-uPA 
for binding to uPAR as well as r-uPA competed with bound 
125I-r-uPAmut, confirming interactions of r-uPA and r-uPA- 
rout with the same uPAR on SMC (Fig. 2). 
However, in contrast o r-uPA, the r -uPAmut (1-100 nM) 
did not induce the SMC to migrate in the Boyden Chamber  
(Fig. 1). To determine whether the r -uPAmut might be acting 
as a uPAR antagonist, we examined its ability to inhibit r- 
uPA-induced SMC migration. As shown in Table 1, the r- 
uPAmut  (100 nM) inhibited SMC migration stimulated by 
the r-uPA in a competitive manner. Thus, binding of ligand 
to uPAR is not sufficient for activation of SMC migration and 
the intact structure of 1 24 amino acids in N-terminus of the 
uPA GFD is essential for chemotactic stimulation of SMC. 
3.2. FGF-2- and PDGF-BB-induced chemotaxis are dependent 
on uPA-uPAR interactions 
PDGF-BB is a potent chemoattractant whose effects on 
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Fig. 2. Binding characteristics of r-u-PA and r-uPAmut to rat SMC. Upper panels: Concentration-dependent ~r'l-r-uPA binding to SMC at 
4°C in the absence (zx) and presence of 100-fold molar excess of r-uPA (©) during a 3 h incubation (left). Scatchard plot of L25I-r-uPA specific 
binding to the SMC (right). Values are given as the mean of triplicate determinations and represent the counts of 12'~'l-r-uPA with specific ra- 
dioactivity 7.25 × l0 s dpm/pmol, bound per 10 6 cells. Lower panels: Competitive binding between 3 nM ~:'l-r-uPA and varying concentrations 
of r-uPA (e) or r-uPAmut (©) to SMC at 4°C (left). The right panel represents competition between 3 nM 1251-r-uPAmut bound to the SMC 
and r-uPA (e) or r-uPAmut (©). All results are the means + S.E.M. of at least 4 experiments. B,, indicates total binding in the absence of unla- 
beled competitor and was 5% and 2.5% of total counts added, for ~251-r-uPA or 12~I-r-uPAmut, respectively. B indicates 125I-r-uPA or ~z~'I-r-uP- 
Amut binding in the presence of a given concentration of unlabelled competitor. Nonspecific binding values were 10.8 +_2.7"/,, of total binding 
for ]251-r-uPA bound and 21.3 +_ 2.1% for 125I-r-uPAmut bound. 
SMC are considered to be dependent on FGF-2 [21]. Since 
endothelial cell migration induced by FGF-2 appears depend- 
ent on plasminogen activator synthesis [22,14], we also inves- 
tigated the extent to which SMC migration induced by either 
PDGF-BB or FGF-2 was dependent on uPA. PDGF-BB and 
FGF-2 (both 50 ng/ml) stimulated SMC migration (Fig. 3). 
The anti-uPA polyclonal antibody completely inhibited the 
FGF-2-stimulated SMC migration; SMC migration stimu- 
lated by PDGF-BB was inhibited by nearly 50% (Fig. 3). 
To confirm the specificity of action of the uPA antibody on 
growth factor-induced cell migration, we compared these in- 
hibitory responses with those of the r-uPAmut. Recombinant 
uPAmut (10 nM) inhibited the PDGF-BB-stimulated cell mi- 
gration to the same extent as did the polyclonal anti-uPA 
antibody (Fig. 3). 
4. Discussion 
In this study we have demonstrated that SMC migration is 
critically dependent on the interaction between urokinase re- 
ceptors on SMC and growth factor-like domain (GFD) of 
uPA. Our studies also indicate that PDGF-BB and FGF-2 
induce SMC migration dependent on uPA production and 
its interactions with SMC surface uPAR. 
Our findings that cultured SMC from rat aorta bind r-uPA 
with high affinity in a saturable and reversible manner are 
consistent with earlier studies on cultured bovine aortic 
SMC [20]. High affinity binding of uPA to this receptor on 
the SMC appear to be slightly reduced by replacement of 
amino acids 1 24 for 13 foreign within the uPA GFD.  The 
analysis of competition isotherms for uPA and uPAmut and 
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Fig. 3. Dependency of the stimulation of SMC migration by FGF-2 
and PDGF-BB on uPA. SMC suspensions were pre-incubated either 
without (hatched bars) or with the anti-uPA antibody (cross-hatched 
bars) or 10 nM r-uPAmut (horizontally lined bars) for 1 h prior to 
placement in the micro Boyden chamber. SMC migration was then 
measured over a 4 h period in the absence (control) and presence of 
FGF-2 (50 ng/ml) or PDGF-BB (50 ng/ml) as described in the 
Methods (see Section 2). *p < 0.05 from SMC migration in the ab- 
sence of the antibody of r-uPAmut. 
numbers of binding sites for these uPA-variants (Fig. 2) in- 
dicates that uPA and uPAmut can interact with the same 
specific receptor. However, in contrast o r-uPA, modification 
within the GFD of uPAmut abolished its chemotactic activity, 
suggesting the antagonistic properties of this uPA-mutant. 
Occupancy of uPAR by uPA not only influences proteolysis 
but also initiates intracellular signalling events promoting cell 
migration. Proteolytically inactive uPA-forms or N-terminal 
fragment of uPA activated protein kinase C, serine phospho- 
rylation [23] and tyrosine kinases [24,25] inducing cell migra- 
tion. One may suggest hat GFD modification in the uPAmut 
could attenuate its ability to initiate signalling events required 
for cell migration. 
Interactions between uPA and uPAR also appear to be 
essential for the efficient stimulation of SMC migration by 
FGF-2 and PDGF-BB. Although these two growth factors 
appear to stimulate cell migration to similar levels as does 
uPA, additional mechanisms are likely to be involved. Growth 
factors are known to upregulate uPAR number on cultured 
bovine SMC and endothelial cells [20,26] and influence 131- 
integrin receptors required for cell migration on collagen 
[19]. Since the r-uPAmut attenuates PDGF-BB-induced mi- 
gration it is possible that intracellular signals initiated by 
the interaction between uPA and uPAR are also involved. 
In conclusion our studies indicate that uPA-uPAR interac- 
tion appeared to be important for the growth factors-depend- 
ent SMC migration and uPA can stimulate SMC migration by 
mechanisms critically dependent on its GFD.  Structural mod- 
ification of 1-24 region within the uPA GFD leads to the loss 
v. Stepanova et al./FEBS Letters 414 (1997) 471~t74 
of its chemotactic properties with no significant changes in 
receptor binding characteristics. 
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